Iovance Biotherapeutics Cash Flow Statement
NASDAQ: IOVAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Iovance Biotherapeutics free cash flow
In fiscal 2025, Iovance Biotherapeutics generated -$302.4 million of operating cash flow and spent $33.8 million on capital expenditures. That left free cash flow of -$336.2 million, a free-cash-flow margin of -127.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Iovance Biotherapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -390.98M | -372.18M | -444.04M | -395.89M | -342.25M | -259.58M | -197.56M | -123.58M | -92.06M | -52.89M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 12.86M | 11.26M | 11.57M | 9.31M | 3.11M | 1.14M | 1.17M | 956.00K | 952.00K | 978.00K |
| Stock-Based Compensation | 61.58M | 109.63M | 62.63M | 84.02M | 69.77M | 40.89M | 24.28M | 20.03M | 11.97M | 18.90M |
| Change in Working Capital | -13.37M | -114.95M | 4.27M | -950.00K | 30.43M | 14.46M | 16.16M | 2.67M | 416.00K | 418.00K |
| Operating Cash Flow | -302.41M | -352.98M | -361.82M | -292.76M | -227.94M | -205.13M | -158.89M | -101.25M | -78.71M | -32.67M |
| Capital Expenditures | -33.84M | -11.07M | -22.29M | -20.43M | -37.57M | -46.79M | -6.92M | -1.20M | -1.03M | -1.52M |
| Investing Cash Flow | 47.50M | -96.41M | -155.24M | 256.45M | 132.00K | -317.85M | 90.03M | -386.28M | 58.68M | 8.89M |
| Debt Issued | — | — | — | — | 1.00M | — | — | — | — | — |
| Financing Cash Flow | 300.77M | 390.66M | 462.96M | 190.15M | 239.27M | 576.42M | 6.13M | 424.31M | 58.69M | 96.90M |
| Net Change in Cash | 47.01M | -59.27M | -56.84M | 153.85M | 11.46M | 53.44M | -62.73M | -63.22M | 38.66M | 73.13M |
| Free Cash Flow | -336.24M | -364.05M | -384.11M | -313.18M | -265.51M | -251.93M | -165.81M | -102.45M | -79.74M | -34.19M |
This table shows 10 annual periods of Iovance Biotherapeutics's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IOVA's reporting calendar. What is a cash flow statement?